PL3810100T3 - Transdermalny system terapeutyczny zawierający asenapinę - Google Patents

Transdermalny system terapeutyczny zawierający asenapinę

Info

Publication number
PL3810100T3
PL3810100T3 PL19730825.7T PL19730825T PL3810100T3 PL 3810100 T3 PL3810100 T3 PL 3810100T3 PL 19730825 T PL19730825 T PL 19730825T PL 3810100 T3 PL3810100 T3 PL 3810100T3
Authority
PL
Poland
Prior art keywords
system containing
therapeutic system
transdermal therapeutic
containing asenapine
asenapine
Prior art date
Application number
PL19730825.7T
Other languages
English (en)
Inventor
Patrick Mohr
René RIETSCHER
René Eifler
Olga BOURQUAIN
Original Assignee
Lts Lohmann Therapie-Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie-Systeme Ag filed Critical Lts Lohmann Therapie-Systeme Ag
Publication of PL3810100T3 publication Critical patent/PL3810100T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL19730825.7T 2018-06-20 2019-06-19 Transdermalny system terapeutyczny zawierający asenapinę PL3810100T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18178876 2018-06-20
PCT/EP2019/066270 WO2019243452A1 (en) 2018-06-20 2019-06-19 Transdermal therapeutic system containing asenapine

Publications (1)

Publication Number Publication Date
PL3810100T3 true PL3810100T3 (pl) 2025-05-12

Family

ID=62715963

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19730825.7T PL3810100T3 (pl) 2018-06-20 2019-06-19 Transdermalny system terapeutyczny zawierający asenapinę

Country Status (12)

Country Link
US (1) US11648213B2 (pl)
EP (1) EP3810100B1 (pl)
JP (1) JP7502199B2 (pl)
KR (1) KR102802121B1 (pl)
CN (2) CN112704672A (pl)
AU (1) AU2019291060B2 (pl)
BR (1) BR112020026099A2 (pl)
CA (1) CA3101420A1 (pl)
ES (1) ES3010131T3 (pl)
MX (1) MX2020014286A (pl)
PL (1) PL3810100T3 (pl)
WO (1) WO2019243452A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
DE102020207642A1 (de) 2020-06-19 2021-12-23 Lts Lohmann Therapie-Systeme Ag Verfahren zur herstellung von asenapin in form seiner freien base
CN116829131B (zh) * 2022-01-12 2024-05-07 新领医药技术(深圳)有限公司 奥氮平透皮给药系统及其制备方法和用途
WO2024145846A1 (zh) * 2023-01-04 2024-07-11 新领医药技术(深圳)有限公司 稳定的透皮给药试剂盒及其制备方法和用途

Family Cites Families (335)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158059A (en) 1976-05-24 1979-06-12 Akzona Incorporated Tension reducing 2,3,4,4a,9,136-hexahydro-dibenz[1,2;5,6]cyclohepta[3,4-c]py
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
JPS61502751A (ja) 1984-07-23 1986-11-27 シエリング，コ−ポレ−シヨン アザタジンの経度デリバリ−
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE69009540T2 (de) 1989-03-15 1994-09-29 Nitto Denko Corp Arzneimittel enthaltendes Heftpflaster.
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
EP0569096A1 (en) 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
ATE167057T1 (de) 1994-03-02 1998-06-15 Akzo Nobel Nv Sublinguales oder bukkales arzneimittel
JP3274579B2 (ja) 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
KR100213465B1 (ko) 1996-11-01 1999-08-02 최좌진 케토프로펜 패취 조성물
AU7767598A (en) 1997-05-26 1998-12-30 Akzo Nobel N.V. Salts of aromatic sulphonic acids
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
GB9714650D0 (en) 1997-07-11 1997-09-17 Strakan Ltd Block copolymer
WO1999032108A1 (en) 1997-12-19 1999-07-01 Akzo Nobel N.V. Org-5222 in the treatment of depression
DE19814083C2 (de) 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
EP1148106B1 (en) 1998-07-29 2004-11-24 Teijin Limited Pressure-sensitive adhesive composition and moisture-permeable pressure-sensitive adhesive tape, pressure-sensitive adhesive drug composition, and pressure-sensitive adhesive tape preparation each containing the composition
DE19918106A1 (de) 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
US20040142024A1 (en) 1999-07-27 2004-07-22 Hisamitsu Pharmaceutical Co., Inc. Patch formulation for external use
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
JP3962684B2 (ja) 2000-11-06 2007-08-22 サムヤン コーポレイション 改善された水分吸収能および接着性を有する経皮投与剤
MXPA03006003A (es) 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
KR100846642B1 (ko) 2001-03-07 2008-07-16 히사미쓰 세이야꾸 가부시키가이샤 첩부제
JP2004527553A (ja) 2001-04-26 2004-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療
GB0119012D0 (en) 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
EP1480629A1 (en) 2002-02-08 2004-12-01 Abbott Laboratories Combination therapy for treatment of schizophrenia
JP4323138B2 (ja) 2002-06-05 2009-09-02 日東電工株式会社 経皮吸収型製剤およびその製造方法
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
ES2323127T3 (es) 2002-08-20 2009-07-07 Euro-Celtique S.A. Forma posologica transdermica que comprende un agente activo y una forma de sal y una forma de base libre de un antagonista.
WO2004098472A1 (en) 2002-08-30 2004-11-18 Watson Pharmaceuticals, Inc. Transdermal delivery systems and methods
WO2004039322A2 (en) 2002-10-29 2004-05-13 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
GB0302662D0 (en) 2003-02-05 2003-03-12 Strakan Ltd Transdermal granisetron
GB0306604D0 (en) 2003-03-21 2003-04-30 Curidium Ltd Second medical use
CA2525366A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
TWI327915B (en) 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight
US20080020028A1 (en) 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
KR20070034451A (ko) 2003-10-10 2007-03-28 오릭세 저분자량 및 고분자량 화합물의 경피전달을 위한 혼합물
ES2626784T3 (es) 2003-10-28 2017-07-26 Noven Pharmaceuticals, Inc. Dispositivo de administración transdérmica de fármacos
JP2007511605A (ja) 2003-11-18 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オランザピン含有経皮薬物送達組成物
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1547650A1 (en) 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US8304431B2 (en) 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1576985A1 (en) 2004-03-18 2005-09-21 B&B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1699488A2 (en) 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
BRPI0507250A (pt) 2004-01-29 2007-06-26 Pfizer Prod Inc combinações para tratar desordens do snc
CA2556160A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
US7650848B2 (en) 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
JP2007526328A (ja) 2004-03-02 2007-09-13 ファルマシア コーポレーション 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物
GB0405200D0 (en) 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
WO2005102393A1 (ja) 2004-04-21 2005-11-03 Hisamitsu Pharmaceutical Co., Inc. 粘着基剤中の吸収促進剤の含有率を高めた外用貼付剤
KR20070014184A (ko) 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
WO2005107808A2 (en) 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
WO2006041538A2 (en) 2004-05-28 2006-04-20 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
WO2006000222A2 (en) 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
US20060019969A1 (en) 2004-07-24 2006-01-26 Laboratorios Dr. Esteve S.A. Use of compounds active on the sigma receptor for the treatment of allodynia
ITMI20041628A1 (it) 2004-08-06 2004-11-06 Bouty S P A Sistema terapeutico a rilascio controllato per uso topico transdermico
GB0417702D0 (en) 2004-08-09 2004-09-08 Merck Sharp & Dohme New uses
US20060039869A1 (en) 2004-08-17 2006-02-23 Daniel Wermeling Intranasal delivery of antipsychotic drugs
ES2596809T3 (es) 2004-10-08 2017-01-12 Noven Pharmaceuticals, Inc. Dispositivo de administración transdérmica de fármacos que incluye un refuerzo oclusivo
US20060078602A1 (en) 2004-10-08 2006-04-13 Noven Pharmaceuticals, Inc. Device for transdermal administration of drugs including acrylic polymers
MX2007004485A (es) 2004-10-15 2007-06-13 Organon Nv Tratamiento de desordenes bipolares y sintomas asociados.
ATE413166T1 (de) 2004-11-22 2008-11-15 Hisamitsu Pharmaceutical Co Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff
US20060150989A1 (en) 2005-01-12 2006-07-13 Peter Migaly Method of diagnosing, treating and educating individuals with and/or about depression
KR20070096058A (ko) 2005-01-28 2007-10-01 쉬바르츠파르마에이지 정신분열증의 부가 요법용 ｓｐｍ 927
US20080138388A1 (en) 2005-02-04 2008-06-12 Hisamitsu Pharmaceutical Co., Inc. Transdermal Absorption Patch
EP1855686A1 (en) 2005-03-01 2007-11-21 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
GB0506139D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
AU2006231281B2 (en) 2005-04-07 2011-04-28 Msd Oss B.V. Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
US7872147B2 (en) 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
KR101422843B1 (ko) 2005-04-07 2014-07-24 머크 샤프 앤 도메 비.브이. 아세나핀 말레에이트의 결정형
US7741358B2 (en) 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
RU2423692C2 (ru) 2005-04-27 2011-07-10 ЮЭмЭн ФАРМА ИНК. Вещества для профилактики и лечения панкреатита
CA2548864C (en) 2005-06-06 2012-12-11 Nitto Denko Corporation Percutaneous absorption-type pharmaceutical preparation
ATE415153T1 (de) 2005-06-06 2008-12-15 Nitto Denko Corp Pharmazeutische zusammensetzung zur perkutane absorption unter verwendung von einem metalchlorid, vorzugsweise natriumchlorid, zur vorbeugung von kohäsionsschwäche
JP5000932B2 (ja) 2005-06-21 2012-08-15 日東電工株式会社 ニコチン含有経皮吸収製剤
US20070015763A1 (en) 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
WO2007017750A1 (en) 2005-08-08 2007-02-15 Pfizer Products Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
WO2007046554A1 (ja) 2005-10-21 2007-04-26 Sumitomo Chemical Company, Limited ジベンゾオキセピノピロール化合物の製造方法、その中間体及び該中間体の製造方法
DE102005050431A1 (de) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
US7888422B2 (en) 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
JP5037831B2 (ja) 2006-02-15 2012-10-03 久光製薬株式会社 凝集力向上及び徐放化の外用貼付剤
US20100234288A1 (en) 2006-03-27 2010-09-16 Panacea Biotec Ltd SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION ON THE BASIS OF RELEASE SYSTEM COMPRISING AN ACID-SOLUBLE POLYMER AND A pH-DEPENDENT POLYMER
TW200812993A (en) 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
US20070259952A1 (en) 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
WO2007137224A2 (en) 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Method of treatment
KR101432698B1 (ko) 2006-06-06 2014-08-22 다우 코닝 코포레이션 실리콘 아크릴레이트 하이브리드 조성물
CA2653827C (en) 2006-06-09 2014-04-08 Dainippon Sumitomo Pharma Co., Ltd. Novel blonanserin tape preparation
TW200817414A (en) 2006-07-05 2008-04-16 Organon Nv Process for the preparation of asenapine and intermediate products used in said process
US7750167B2 (en) 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
ATE496894T1 (de) 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
US20080090892A1 (en) 2006-10-06 2008-04-17 N.V. Organon Amorphous asenapine and processes for preparing same
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
KR101408488B1 (ko) 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법
EP2638906A1 (en) 2006-12-01 2013-09-18 Nitto Denko Corporation Stabilized adhesive preparation containing donepezil
CN101563312A (zh) 2006-12-22 2009-10-21 住友化学株式会社 阿塞那平合成中间体的制备方法
US7875729B2 (en) 2007-01-05 2011-01-25 Synthon Bv Process for making asenapine
SG178716A1 (en) 2007-01-16 2012-03-29 Ipintl Llc Novel composition for treating metabolic syndrome
US20080226698A1 (en) 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
FR2913882B1 (fr) 2007-03-20 2009-05-01 Oreal Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose
WO2008141438A1 (en) 2007-05-17 2008-11-27 Sunnybrook Health Sciences Centre Gabaergic modulators for treating airway conditions
WO2008148515A1 (en) 2007-06-05 2008-12-11 Synthon B.V. Intranasal administration of asenapine and pharmaceutical compositions therefor
WO2009000890A2 (en) 2007-06-27 2008-12-31 N.V. Organon Medication container
JP5245428B2 (ja) 2007-07-06 2013-07-24 住友化学株式会社 トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
JP5224163B2 (ja) 2007-07-24 2013-07-03 コスメディ製薬株式会社 経皮吸収テープ製剤
WO2009017453A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
CA2719824A1 (en) 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
US20090209608A1 (en) 2007-08-29 2009-08-20 Protia, Llc Deuterium-enriched asenapine
WO2009036056A1 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
JP5653753B2 (ja) 2007-09-10 2015-01-14 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｓｎｐ遺伝子型に基づくｑｔ延長の予測
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
EP2254577A1 (en) 2007-12-26 2010-12-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
WO2009087058A1 (en) 2008-01-04 2009-07-16 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8529441B2 (en) 2008-02-12 2013-09-10 Innurvation, Inc. Ingestible endoscopic optical scanning device
EP2254598B1 (en) 2008-02-13 2013-07-10 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
JP5537412B2 (ja) 2008-02-27 2014-07-02 久光製薬株式会社 貼付製剤
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES
JP5301190B2 (ja) 2008-03-31 2013-09-25 積水メディカル株式会社 貼付剤
WO2009135091A1 (en) 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
BRPI0913214B1 (pt) 2008-05-30 2022-05-17 Mylan Laboratories Inc Dispositivo de fornecimento de drogas transdérmico e método de fabricação do mesmo
EP2299983A4 (en) 2008-07-24 2012-10-10 Handa Pharmaceuticals Llc ATYPICAL ANTIPSYCHOTIC FORMULATION STABILIZED
WO2010020642A1 (en) 2008-08-20 2010-02-25 Brainco Biopharma, S.L. Stxbp1 as psychiatric biomarker in murine model system and their uses
EP2337564A1 (en) 2008-09-04 2011-06-29 NeuroSearch A/S A method for combating adverse effects arising from antipsychotic treatment
WO2010060742A1 (en) 2008-11-03 2010-06-03 Solvay Pharmaceuticals B.V. Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders
WO2010073326A1 (ja) 2008-12-24 2010-07-01 ニチバン株式会社 経皮吸収型製剤
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
MX353752B (es) 2009-01-20 2018-01-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco.
CA2792484C (en) 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
US8579865B2 (en) 2009-03-20 2013-11-12 Antares Pharma, Inc. Hazardous agent injection system
WO2010110914A2 (en) 2009-03-27 2010-09-30 Zirus, Inc. Mammalian genes involved in infection
EP2236138A1 (en) 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood and anxiety disorders
EP2236157A1 (en) 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Pipamperone and a second agent in treating mood and anxiety disorders
EP2413935A1 (en) 2009-03-30 2012-02-08 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood disorders
WO2010119455A2 (en) 2009-04-15 2010-10-21 Sun Pharma Advanced Research Company Ltd. An injectable sustained release pharmaceutical composition
EP2421553A4 (en) 2009-04-21 2012-11-28 Sanomune Inc TISSUE KALLICREIN FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER
RU2544702C2 (ru) 2009-04-24 2015-03-20 Хенкель Корпорейшн Клеи на основе силикон-акрилового гибридного полимера
TWI471127B (zh) 2009-04-29 2015-02-01 Intervet Int Bv 供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物
JP5758290B2 (ja) 2009-05-01 2015-08-05 久光製薬株式会社 経皮吸収型製剤
WO2010127674A1 (en) * 2009-05-06 2010-11-11 Sunin K/S Transdermal compositions of asenapine for the treatment of psychiatric disorders
KR101435296B1 (ko) 2009-06-24 2014-08-27 머크 샤프 앤 도메 비.브이. 아세나핀을 함유하는 주사가능한 제제 및 그를 사용한 치료 방법
US20110306596A1 (en) 2009-07-27 2011-12-15 Auspex Pharmaceuticals, Inc. Benzazepine inhibitors of gamma-secretase
TW201118102A (en) 2009-07-29 2011-06-01 Organon Nv Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
EP2473166A2 (en) 2009-08-31 2012-07-11 Eric B. Schneider Treatment and prevention of secondary injury after trauma or damage to the central nervous system
CA2777843A1 (en) 2009-10-16 2011-04-21 University Of South Florida Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors
US20110262442A1 (en) 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
US9629920B2 (en) 2009-12-18 2017-04-25 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
WO2011085188A1 (en) 2010-01-07 2011-07-14 Eurand, Inc. Pharmaceutical compositions comprising anti-psychotic drugs
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
WO2011084851A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Asenapine produrugs
ITMI20100260A1 (it) 2010-02-19 2011-08-20 Giulio Scigliano Composizione farmaceutica contenente un farmaco per ridurre gli effetti collaterali dei farmaci antipsicotici
WO2011105486A1 (ja) 2010-02-24 2011-09-01 久光製薬株式会社 貼付剤
JP5615899B2 (ja) 2010-02-24 2014-10-29 久光製薬株式会社 経皮吸収製剤
WO2011107855A2 (en) 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
WO2011120044A1 (en) 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
EP2564873A4 (en) 2010-04-28 2013-11-06 Hisamitsu Pharmaceutical Co MEANS FOR THE SUPPRESSION OF SKIN IRRITATIONS AND TRANSDERMAL PREPARATION THEREOF
WO2011143755A1 (en) 2010-05-21 2011-11-24 Serdar Dursun Compositions and methods of treating schizophrenia
CN101851242B (zh) 2010-05-25 2013-07-24 上海皓元生物医药科技有限公司 阿塞那平中间体的制备方法
EP2582704A4 (en) 2010-06-18 2014-04-02 Reddys Lab Ltd Dr Asenapine MALEATE
EP2598496B1 (en) 2010-07-29 2014-03-19 Laboratorios Lesvi, S.L. Novel process for the preparation of asenapine
JP2013540748A (ja) 2010-09-16 2013-11-07 コーネル ユニバーシティー 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法
WO2012038975A2 (en) 2010-09-22 2012-03-29 Msn Laboratories Limited Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
CA2811465A1 (en) 2010-09-27 2012-04-05 Alphora Research Inc. Process for the preparation of tetracyclic derivatives and intermediate products used in the process
WO2012065110A2 (en) 2010-11-12 2012-05-18 Promentis Pharmaceuticals, Inc. S-protected cysteine analogs and related compounds
CA2816609A1 (en) 2010-11-12 2012-05-18 Promentis Pharmaceuticals, Inc. S-t-butyl protected cysteine di-peptide analogs and related compounds
WO2012066565A2 (en) 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
CA2815898C (en) 2010-11-17 2018-12-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
US20130217681A1 (en) 2010-11-26 2013-08-22 Technion Research And Development Foundation Ltd. Method and composition for weight-gain management
CN104606142A (zh) 2010-11-26 2015-05-13 约翰内斯堡威特沃特斯兰德大学 用于治疗阿尔茨海默病的可植入头颅中的装置
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
JP6013364B2 (ja) 2010-12-23 2016-10-25 アルカーメス ファーマ アイルランド リミテッド マルチプルａｐｉローディングプロドラッグ
EP2468751B1 (en) 2010-12-24 2016-03-16 Medichem, S.A. Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2012114325A1 (en) 2011-02-23 2012-08-30 Mapi Pharma Limited Polymorphs of asenapine maleate
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
CN103501770B (zh) 2011-04-18 2015-04-29 久光制药株式会社 贴附剂的制造方法及贴附剂
CN102229613B (zh) 2011-04-27 2013-08-07 上海华升生物科技有限公司 阿森纳平的合成工艺
ITMI20110734A1 (it) 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
EP2524921A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
EP2524920A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Asenapine Hydrochloride Salt Forms
WO2012156676A1 (en) 2011-05-18 2012-11-22 Laboratorios Lesvi S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
US9505771B2 (en) 2011-05-18 2016-11-29 Laboratories Lesvi S.L. Stable micronised monoclin form of asenapine maleate and its synthesis
DE102011076653A1 (de) 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
WO2013002584A2 (ko) 2011-06-28 2013-01-03 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
BR112013033417A2 (pt) 2011-06-29 2016-08-16 Otsuka Pharma Co Ltd compostos terapêuticos e métodos relacionados de uso
WO2013024492A2 (en) 2011-07-01 2013-02-21 Megafine Pharma (P) Ltd. A process for the preparation of asenapine and novel salts thereof
ES2757960T3 (es) 2011-07-07 2020-04-30 Teikoku Seiyaku Kk Parche cutáneo adhesivo que contiene fármaco antagonista receptor de serotonina
WO2013011461A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of asenapine maleate
EP2736890A4 (en) 2011-07-28 2015-07-15 Promentis Pharm Inc Cysteine PRODRUGS
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
CN102952144A (zh) 2011-08-29 2013-03-06 上海华拓医药科技发展股份有限公司 阿森纳平马来酸盐的晶型、制备方法及其药物组合物
WO2013035109A1 (en) 2011-09-08 2013-03-14 Mylan Laboratories Ltd Improved process for the preparation of asenapine maleate
WO2013040419A1 (en) 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
TWI583401B (zh) 2011-10-24 2017-05-21 布雷本製藥股份有限公司 可植入替紮尼定組合物及其治療方法
WO2013061247A1 (en) 2011-10-24 2013-05-02 Alembic Pharmaceuticals Limited Novel process for the preparation of asenapine
US20140350081A1 (en) 2011-11-04 2014-11-27 Purdue Research Foundation Insect g-coupled receptors useful as targets for insecticides and compounds and reagents identified using the same
WO2013080069A1 (en) 2011-11-28 2013-06-06 Ranbaxy Laboratories Limited Process for the preparation of asenapine intermediate
JP2013139554A (ja) 2011-11-29 2013-07-18 Dow Corning Corp シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法
AU2012345659B2 (en) 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN103183680A (zh) 2011-12-27 2013-07-03 上海华拓医药科技发展股份有限公司 阿森那平的制备方法
WO2013114400A2 (en) 2012-01-20 2013-08-08 Rubicon Research Private Limited Compressed pharmaceutical compositions of atypical antipsychotics
CN103254201B (zh) 2012-02-21 2016-04-13 四川科伦药物研究有限公司 一种阿塞那平的制备方法
DK2825208T3 (en) 2012-03-14 2017-09-11 Levicept Ltd P75NTR-NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE
DE102012205493A1 (de) 2012-04-03 2013-10-10 Acino Ag Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem
US9658211B2 (en) 2012-04-18 2017-05-23 Hemoshear, Llc In vitro model for pathological or physiologic conditions
KR20130120648A (ko) 2012-04-26 2013-11-05 에스에프씨 주식회사 벤조사이클로플루오렌계 화합물 및 이를 포함하는 유기전계발광소자
CN102657635B (zh) 2012-05-04 2013-08-07 上海现代药物制剂工程研究中心有限公司 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法
WO2013170000A1 (en) 2012-05-09 2013-11-14 The Rockfeller University Methods and compositions for activity dependent transcriptome profiling
CN102746209A (zh) 2012-06-20 2012-10-24 盛世泰科生物医药技术(苏州)有限公司 一种3-（2-（4-氯苯氧基）苯基）-1-甲基-2,4-二酮的合成方法
WO2013190481A1 (en) 2012-06-21 2013-12-27 Alembic Pharmaceuticals Limited Process for preparing asenapine and salts of intermediates thereof
EP2878299B1 (en) 2012-07-26 2018-05-16 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
US8986677B2 (en) 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
CA2885941A1 (en) 2012-09-28 2014-04-03 Delpor, Inc. Device and method for sustained release of antipsychotic medications
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
CN112402421A (zh) 2012-10-25 2021-02-26 大塚制药株式会社 含有依匹唑派或其盐的预防和/或治疗剂
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014078377A1 (en) 2012-11-14 2014-05-22 Agenebio, Inc. Methods and compositions for treating schizophrenia
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CN102976998A (zh) 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 一种3 -（5-氯-2-苯氧基-苯基）-1-甲基-吡咯烷-2,4-二酮的合成方法
RU2663289C2 (ru) 2012-11-26 2018-08-03 Юниверсити Оф Кейптаун Производные фенотиазина и их применение против туберкулеза
CN102976929A (zh) 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 一种（4-氯-2-苯氧基苯基）乙酸的合成方法
JP2014105205A (ja) 2012-11-30 2014-06-09 Medical Front Co Ltd 医用貼付剤
WO2014090386A1 (en) 2012-12-11 2014-06-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
WO2014100501A1 (en) 2012-12-20 2014-06-26 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
TWI646091B (zh) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
MX366230B (es) 2012-12-28 2019-07-03 Noven Pharma Composiciones multipolimericas para liberación transdermica de farmaco.
CN103893139B (zh) 2012-12-28 2018-06-08 石药集团中奇制药技术（石家庄）有限公司 一种阿塞那平组合物及其制备方法
CN103120688A (zh) 2013-01-11 2013-05-29 盛世泰科生物医药技术(苏州)有限公司 一种闪释制剂的药物组合
CN103965206A (zh) 2013-01-29 2014-08-06 北京京卫燕康药物研究所有限公司 一种阿色纳品马来酸盐的新晶型及制备方法
US10154856B2 (en) 2013-02-06 2018-12-18 Mark SILLENDER Therapeutic substance transfer catheter and method
CN103083284B (zh) 2013-02-06 2014-08-06 上海现代药物制剂工程研究中心有限公司 膜状制剂及其制备方法
CN103099799B (zh) 2013-02-06 2014-08-06 上海现代药物制剂工程研究中心有限公司 复合膜状制剂及其制备方法
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
CN103113379A (zh) 2013-03-12 2013-05-22 盛世泰科生物医药技术(苏州)有限公司 阿塞那平马来酸盐的合成工艺
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
WO2014152965A2 (en) 2013-03-14 2014-09-25 The Children's Hospital Of Philadelphia Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
WO2014160026A2 (en) 2013-03-14 2014-10-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof
WO2014160167A1 (en) 2013-03-14 2014-10-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions comprising aromatic polyurethanes and methods of treatment thereof
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
US20160022571A1 (en) 2013-03-14 2016-01-28 Braeburn Pharmaceuticals Bvba Sprl Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
US20140276479A1 (en) 2013-03-14 2014-09-18 Noven Pharmaceuticals, Inc. Transdermal drug delivery system with overlay
WO2014145680A1 (en) 2013-03-15 2014-09-18 Ameritox, Ltd. Methods of normalizing measured drug concentrations and testing for potential non-compliance with a drug treatment regimen
AR095259A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
BR112015023922A2 (pt) 2013-03-15 2017-07-18 Als Mountain Llc composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
HK1220109A1 (zh) 2013-03-15 2017-04-28 Nal Pharmaceutical Group Limited 含卡巴拉汀的经皮给药系统
JP6129632B2 (ja) 2013-04-24 2017-05-17 帝國製薬株式会社 貼付剤
CN103254202A (zh) 2013-05-19 2013-08-21 甘肃皓天化学科技有限公司 阿塞纳平的制备方法
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN103342707B (zh) 2013-06-28 2015-09-02 甘肃皓天化学科技有限公司 用于制备阿塞纳平中间体的制备方法
IN2013MU02206A (pl) 2013-06-28 2015-06-12 Alembic Pharmaceuticals Ltd
CN103351393B (zh) 2013-07-03 2016-04-06 华裕(无锡)制药有限公司 用于制备阿森那平之还原剂及阿森那平之制备方法
WO2015027342A1 (en) 2013-08-30 2015-03-05 Mcmaster University Microgel compositions for delivery of substances to the brain
CN104447770A (zh) 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 阿塞那平化合物
CN104447771A (zh) 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 一种稳定的马来酸阿塞那平化合物
US10098893B2 (en) 2013-10-03 2018-10-16 Northwestern University Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
US9757330B2 (en) 2013-10-18 2017-09-12 Industrial Technology Research Institute Recipe for in-situ gel, and implant, drug delivery system formed thereby
WO2015071831A1 (en) 2013-11-18 2015-05-21 Piramal Enterprises Limited An improved process for minimising the formation of dehalogenated byproducts
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CA2928772A1 (en) 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
KR20160096155A (ko) 2013-12-12 2016-08-12 히사미쓰 세이야꾸 가부시키가이샤 커버재가 부착된 첩부제 및 커버재가 부착된 첩부제 키트
CN103772402A (zh) 2014-01-07 2014-05-07 万特制药(海南)有限公司 一种新的阿塞那平马来酸盐粗品精制方法
CN103772400A (zh) 2014-01-07 2014-05-07 万特制药(海南)有限公司 反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法
CN103772401A (zh) 2014-01-07 2014-05-07 万特制药(海南)有限公司 11-氯-2,3,3a,12b-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯-1-酮的一种新精制方法
CN103760258A (zh) 2014-01-07 2014-04-30 万特制药(海南)有限公司 一种用液相色谱法分离测定马来酸阿塞那平有关物质的方法
CN103760280A (zh) 2014-01-10 2014-04-30 万特制药(海南)有限公司 一种用液相色谱法分离测定阿塞那平中间体有关物质的方法
US9782398B2 (en) 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
US20170007537A1 (en) 2014-02-18 2017-01-12 Hetero Research Foundation Pharmaceutical compositions of asenapine
CN106456662A (zh) 2014-02-24 2017-02-22 奥利金制药公司 口服给药的戊聚糖多硫酸盐的组合物及其使用方法
WO2015127556A1 (en) 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating defecation in a patient in need thereof
WO2015127557A1 (en) 2014-02-28 2015-09-03 Centre For Addiction And Mental Health Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain
WO2015127558A1 (en) 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
CN103864802B (zh) 2014-03-31 2016-08-17 四川科伦药业股份有限公司 马来酸阿塞那平的制备方法
CN104974167B (zh) 2014-04-02 2019-01-04 洋浦慧谷医药有限公司 阿塞那平的制备方法以及用于制备阿塞那平的中间体
CN104974168B (zh) 2014-04-02 2019-01-04 洋浦慧谷医药有限公司 阿塞那平的制备方法以及用于制备阿塞那平的中间体
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
CN104000800A (zh) 2014-04-28 2014-08-27 万特制药(海南)有限公司 马来酸阿塞那平口腔速溶膜剂及其制备方法
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
EP3151906B1 (en) 2014-06-03 2019-12-11 Pop Test Abuse Deterrent Technology LLC Drug device configured for wireless communication
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
CN104133010B (zh) 2014-07-01 2019-11-29 北京万全德众医药生物技术有限公司 高效液相色谱法分离分析阿西马朵林中间体及光学异构体
CN104133012B (zh) 2014-07-02 2020-01-07 北京万全德众医药生物技术有限公司 一种高效液相色谱法测定马来酸阿塞那平消旋体的方法
US10071090B2 (en) 2014-07-18 2018-09-11 Buzzz Pharmaceuticals Limited Oxymorphone transdermal patch
CN104098580B (zh) 2014-07-22 2016-04-13 成都百裕科技制药有限公司 一种阿塞那平关键中间体的制备方法
AU2015296807A1 (en) 2014-07-31 2017-03-09 Noven Pharmaceuticals, Inc. Silicone-containing acrylic polymers for transdermal drug delivery compositions
ES2562684B1 (es) 2014-08-04 2017-02-06 Consejo Superior De Investigaciones Científicas (Csic) Método de monitorización de tratamiento antipsicótico
WO2016023658A1 (en) 2014-08-14 2016-02-18 Alrise Biosystems Gmbh Injectable formulations of asenapine
JP2016056142A (ja) 2014-09-11 2016-04-21 第一三共株式会社 Ｐｄｅ１０ａ阻害薬と抗精神病薬の組み合わせ
CN104297366A (zh) 2014-09-24 2015-01-21 万特制药(海南)有限公司 马来酸阿塞那平及其杂质的液相分析方法
EA201790693A1 (ru) 2014-10-14 2017-09-29 Скюлпт Б.В. Коррекция фигуры
TWI621434B (zh) 2014-10-24 2018-04-21 朗齊生物醫學股份有限公司 千憂解藥物應用於癌症治療
EP3020782B1 (en) 2014-11-11 2018-08-01 SFC Co., Ltd. An electroluminescent compound and an electroluminescent device comprising the same
CA2965157A1 (en) 2014-11-25 2016-06-02 Nanocopoeia, Llc Method of converting a crystalline compound to an amorphous compound, method of increasing the solubility of a crystalline compound in a biorelevant fluid, and nanoparticles that achieve supersaturation
EP3227678A4 (en) 2014-12-01 2018-07-11 The Feinstein Institute for Medical Research Use of striatal connectivity patterns for evaluating antipsychotic agents
AU2015358343A1 (en) 2014-12-05 2017-06-01 Myriad Genetics, Inc. Biomarkers for distinguishing mood disorders
EP3031458A1 (en) 2014-12-09 2016-06-15 Iproteos S.L. Use of 1-[(2-phenylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole in the treatment of schizophrenia-associated cognitive deficits
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
WO2016114655A1 (en) 2015-01-12 2016-07-21 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
JP6176413B2 (ja) 2015-01-30 2017-08-09 東洋インキＳｃホールディングス株式会社 貼付剤
KR102048682B1 (ko) 2015-02-09 2019-11-27 다우 실리콘즈 코포레이션 다중상 실리콘 아크릴 하이브리드 점탄성 조성물 및 이의 제조 방법
DK3261640T3 (da) 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser
JP6360614B2 (ja) 2015-03-02 2018-07-18 久光製薬株式会社 貼付剤
KR20160107610A (ko) 2015-03-04 2016-09-19 한국과학기술원 대사 질환의 예방 또는 치료용 조성물
ITUB20150635A1 (it) 2015-04-14 2016-10-14 Giuseppe Lotito Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore.
EP3285753A1 (en) 2015-04-22 2018-02-28 CeMM - Forschungszentrum für Molekulare Medizin GmbH Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
WO2016176519A1 (en) 2015-04-28 2016-11-03 Proove Biosciences, Inc. System and method for processing genotype information relating to drug metabolism
CN108135860A (zh) 2015-06-22 2018-06-08 考里安国际公司 包含难溶性治疗剂的透皮粘合剂组合物
ES2598248B1 (es) 2015-06-26 2017-12-18 Centro De Investigación Biomédica En Red Método in vitro y kit para el pronóstico o predicción de la respuesta al tratamiento con agentes antipsicóticos por parte de pacientes que han sufrido un primer episodio psicótico
CN112843023A (zh) * 2015-07-27 2021-05-28 久光制药株式会社 含有阿塞那平的贴剂的制造方法
WO2017018322A1 (ja) 2015-07-27 2017-02-02 久光製薬株式会社 アセナピン含有貼付剤
CN105566336A (zh) 2016-01-08 2016-05-11 万特制药(海南)有限公司 一种制备阿塞那平去甲基杂质的新方法
CN105693735A (zh) 2016-01-15 2016-06-22 万特制药(海南)有限公司 马来酸阿塞那平一种制备方法
WO2017131034A1 (ja) 2016-01-28 2017-08-03 久光製薬株式会社 経皮吸収製剤
JP6658201B2 (ja) 2016-03-28 2020-03-04 東洋インキＳｃホールディングス株式会社 貼付剤
KR20160108258A (ko) 2016-06-20 2016-09-19 한국과학기술원 대사 질환의 예방 또는 치료용 조성물
BR112019000706A8 (pt) * 2016-07-15 2022-12-06 Pasteur Institut Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
KR102424270B1 (ko) 2016-07-27 2022-07-25 코리움, 인크. 경구 전달과 생물학적으로 동등한 약물동역학을 가진 경피 전달 시스템
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统

Also Published As

Publication number Publication date
EP3810100A1 (en) 2021-04-28
KR20210022656A (ko) 2021-03-03
JP2021529737A (ja) 2021-11-04
AU2019291060B2 (en) 2024-09-05
JP7502199B2 (ja) 2024-06-18
EP3810100B1 (en) 2024-11-20
ES3010131T3 (en) 2025-04-01
AU2019291060A1 (en) 2020-11-26
CN110958876A (zh) 2020-04-03
CN112704672A (zh) 2021-04-27
US20210251915A1 (en) 2021-08-19
CA3101420A1 (en) 2019-12-26
WO2019243452A1 (en) 2019-12-26
KR102802121B1 (ko) 2025-05-02
CN110958876B (zh) 2020-12-18
MX2020014286A (es) 2021-03-25
BR112020026099A2 (pt) 2021-03-23
US11648213B2 (en) 2023-05-16

Similar Documents

Publication Publication Date Title
PL3338768T3 (pl) Transdermalny system terapeutyczny zawierający asenapinę
SG11202104461XA (en) Therapeutic methods
GB201804255D0 (en) Macrophage-based therapy
GB201616839D0 (en) Therapeutic compounds
SG11202103253YA (en) Therapeutic compounds
GB201819853D0 (en) Therapy
SI3866850T1 (sl) Kombinirana terapija melanoma
ZA201805046B (en) Therapeutic compounds
SG11202010676TA (en) Improved t-cell therapy
GB201716942D0 (en) Therapeutic compounds
EP3265067A4 (en) Oxybutynin-xanomeline transdermal therapeutic system combinations
GB201617339D0 (en) Therapeutic compounds
GB201808150D0 (en) Therapeutic compounds
GB201908885D0 (en) Therapeutic compounds
IL263821A (en) Medicinal compounds
EP3242659A4 (en) Oxybutynin transdermal therapeutic system combination
GB201817385D0 (en) Therapy
HK40051168A (en) Transdermal therapeutic system containing asenapine
HK40013237A (en) Transdermal therapeutic system containing asenapine
GB201712884D0 (en) Novel therapeutic compounds
HK40051113A (en) Transdermal therapeutic system containing rivastigmine
HK40060703A (en) Transdermal therapeutic system
GB201911574D0 (en) Therapeutic compounds
GB201911580D0 (en) Therapeutic compounds
GB201819936D0 (en) Therapeutic methods